Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.

@article{Camodeca2016DiscoveryOA,
  title={Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.},
  author={Caterina Camodeca and Elisa Nuti and Livia Tepshi and Silvia Boero and Tiziano Tuccinardi and Enrico A Stura and Alessandro Poggi and Maria Raffaella Zocchi and Armando Rossello},
  journal={European journal of medicinal chemistry},
  year={2016},
  volume={111},
  pages={193-201}
}
Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10… CONTINUE READING